Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 13Gastrointestinal 7Breast 3Thoracic 2Sarcoma 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Myeloproliferative Disorders 3Multiple Myeloma 2Lymphoma, Extranodal NK-T-Cell 2Lymphohistiocytosis, Hemophagocytic 2Lung Neoplasms 2Leukemia 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Thyroid Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis 1Glioblastoma 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

selinexor 1pemigatinib 1pembrolizumab 1Trastuzumab 1Gemcitabine 1Fentanyl 1Docetaxel 1Cisplatin 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Gemcitabine × Myeloid × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡